Navigation Links
Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
Date:7/21/2009

JERUSALEM, Israel, July 21 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study marks Oramed's first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed's trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients.

Oramed's oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion.

Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, "These results demonstrate that Oramed's oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal."

Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on type 2 diabetic patients.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://ww
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
2. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
3. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
4. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
5. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
6. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
7. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
8. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
9. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
10. Amylin Pharmaceuticals to Webcast Second Quarter Results
11. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... as well as changes to Martine Rothblatt , ... United Therapeutics announced the promotion of ... Executive Officer and David Zaccardelli , Pharm.D. to ... with these promotions, Dr. Rothblatt,s title will change from ...
(Date:12/17/2014)... FRANCISCO, Calif. , Dec. 17, 2014 /PRNewswire/ ... of a Phase 2 study evaluating the investigational ... treatment of patients with severe, chronic itch who ... standard of care, including topical steroids and antihistamines. ... percent change in Visual Analog Scale (VAS) itch ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 METTLER ... inline PVM tool, ParticleView V19 with PVM ... situ probe-based particle vision and measurement tool continuously ... process conditions. ParticleView V19 then automatically prepares a ... tracking particle size and concentration changes. This compelling ...
(Date:12/15/2014)... , Dec. 15, 2014 Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology,  ... and collaborators of its exVive3D TM Human ... available in full commercial release on November 18, ... resulting in several awards for innovation. ...
Breaking Biology Technology:United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... CITY, April 26, 2011 AAPC ( www.aapc.com ) ... 30, and once again lowered prices from the previous year. Prices ... "While the primary purpose of a price reduction was to ... take advantage of the significant savings," said Olga Starynskaya, coding books ...
... April 25, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... the first quarter 2011 on Monday, May 9, 2011 before ... also conduct a conference call that day at 10:00 a.m. ... 2011.  The presentation slides to be used during the call ...
... the uptake of medicines and nutrients varies from person to ... Universiteit Brussel, one of the two lead researchers in the ... Treatments and doses could be determined on the basis of ... of the gut types could also lead to other medical ...
Cached Biology Technology:AAPC Lowers Prices on Medical Coding Books, Again 2Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011 2Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011 3People fall into 3 categories of gut microbiota 2
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... of a gassy chemical messenger to dilate blood vessels and ... cells so that the immune system can recognize and attack ... , Tests at Hopkins on mice with implanted colon and ... in sildenafil-treated animals, compared to mice that did not get ...
... can lead to trouble when it comes to treating ... Oct. 1 issue of The Journal of Infectious Diseases, ... infected patients with suppressed immunity represent, next to children ... says Jean-Pierre Van geertruyden, MD, MSc, lead author of ...
... breast cancer has taken on a new meaning in the ... new therapies and detection techniques, significantly improving long-term survival for ... on these successes, researchers are now harnessing what they have ... methods of prevention to reduce the total incidence of the ...
Cached Biology News:'Erectile dysfunction' drugs heighten natural anti-cancer activity 2Malaria treatment efficacy compromised in certain HIV-positive patients 2Novel vaccine shows promise against early-stage breast cancer 2
... Immunogen: Synthetic Peptide: M(1) E F ... G P P T M D L E(19) ... mouse cells.,PA1-072 has been successfully used in Western ... detects an ~86 kDa protein representing Mint3 from ...
... 3.5 is a user-friendly statistical software package ... to perform statistical analysis without being a ... your data and research and SigmaStat suggests ... against the tests underlying assumptions and suggests ...
... a chemiluminescent signal enhancing reagent that ... the signal obtained with all ECL ... Plus is derived from a powerful, ... or chemiluminescent substrate enhancers, ChemiLucent™ Plus ...
... Control at its Best: DASGIPs Process ... Online Changes & comprehensive documentation for ... parameters auch as pH, dissolved oxygen, ... and changeable online. Profiles, e.g. constant ...
Biology Products: